Molecular Sherlock

Molecular Sherlock

Share this post

Molecular Sherlock
Molecular Sherlock
DFV890 (NLRP3 inhibitor) ✔️
Inflammation & Immunology

DFV890 (NLRP3 inhibitor) ✔️

Novartis AG

Mar 13, 2023
∙ Paid
2

Share this post

Molecular Sherlock
Molecular Sherlock
DFV890 (NLRP3 inhibitor) ✔️
1
Share

Confirmed correct on May 17, 2024 in Figure 1 of the Clin. Transl. Sci. paper describing the ph1 study.

DFV890 (formerly IFM-2427) is an oral NLRP3 inhibitor acquired by Novartis (NVS 0.00%↑ ) from IFM Tre in 2019. It is currently being developed for a variety of inflammatory diseases, including osteoarthritis, for which it is in phase 2 trials (NCT04886258).

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Victoria Yan
Market data by Intrinio
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share